SEP 13, 2020 7:30 AM PDT

Should we be treating kidney cancer differently?

New research published in the journal Clinical Cancer Research is questioning how we treat kidney tumors. According to the findings of scientists from the Huntsman Cancer Institute at the University of Utah, the proteins HIF-1α and HIF-2α play different roles in tumor development than was previously understood. These findings suggest a new to completely rethink the way we attack kidney cancer.

"Prior research in kidney cancer suggests a paradigm in which HIF-1α plays an anti-tumor role, whereas HIF-2α plays a pro-tumor role, but this was determined primarily using cell lines and animal models," said Mei Koh, Ph.D., an HCI investigator and assistant professor in the Department of Pharmacology and Toxicology at the U of U.

In this study, instead of relying on cell lines and animal models, the research team used tissue from over 380 patients with from clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer. They analyzed the levels of HIF proteins, tumor grade, stage, and patient outcome, determining that in fact HIF-1α is associated with high-grade, metastatic tumors. Additionally, HIF-1α was found to be associated with decreased patient survival and increased resistance to therapy.

On the other hand, the team just as unexpectedly found that HIF-2α was associated with low-grade tumors, no metastasis, and longer life. "The entire team was surprised that our findings were almost exactly opposite to what we had expected," Koh said.

Photo: Pexels

"Our view of the HIFs in kidney cancer may need to be revised. We found that HIF-1α, the presumed tumor suppressor, was an indicator of poor patient outcome. HIF-2α, the presumed tumor driver, was significantly associated with better patient outcome. Of note, HIF-1α was detected mainly in tumor-associated macrophages, which are immune cells of the patient, but not within the cells of the tumor. This suggests that these immune cells could play an important role in tumor progression. HIF-2α was detected exclusively within tumor cells."

Based on these findings, the team says there is a need to reevaluate the role of both proteins, considering HIF-1α as a therapeutic target as well as a marker of disease progression.

Sources: Clinical Cancer Research, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
NOV 18, 2020
Genetics & Genomics
Choosing an NGS workflow: What are you looking for?
NOV 18, 2020
Choosing an NGS workflow: What are you looking for?
  It’s easy to be overwhelmed by the number of workflows that are available for NGS. How do you choose? While ...
NOV 30, 2020
Cancer
Using deep learning to identify breast cancer biomarkers in mammograms
NOV 30, 2020
Using deep learning to identify breast cancer biomarkers in mammograms
A team from Massachusetts General Hospital (MGH) has developed a deep learning model capable of predicting a patient&rsq ...
DEC 02, 2020
Cancer
Telomere shortening doesn't only indicate ageing...
DEC 02, 2020
Telomere shortening doesn't only indicate ageing...
While telomere shortening has been thought to be an adverse sign of aging, new research suggests that the shortening of ...
DEC 29, 2020
Immunology
Cancer-Killing Viruses Enter in Stealth Mode, Penetrate Immune Barrier
DEC 29, 2020
Cancer-Killing Viruses Enter in Stealth Mode, Penetrate Immune Barrier
Viruses that when administered to patients preferentially attack and kill cancer cells, leaving normal tissues unscathed ...
DEC 31, 2020
Cancer
Does inflammation make ADT symptoms worse?
DEC 31, 2020
Does inflammation make ADT symptoms worse?
A new study published in the journal Cancer considers the impact of inflammation on prostate cancer patients underg ...
JAN 18, 2021
Cancer
An "E-Nose" Could Help Doctors Diagnose Breast Cancer and Its Subtypes
JAN 18, 2021
An "E-Nose" Could Help Doctors Diagnose Breast Cancer and Its Subtypes
Breast cancer is one of the most well-studied cancers in modern medicine. Diagnostics can already differentiate between ...
Loading Comments...